HistoSonics Secures $102M in Oversubscribed Series D Round to Scale Non-Invasive Histotripsy Platform
HistoSonics has closed an oversubscribed $102 million Series D financing round, led by Alpha Wave Ventures. New investors Amzak Health and HealthQuest Capital joined existing backers Johnson & Johnson Innovation…
DermBiont Unveils SM-020 for Basal Cell Carcinoma and Gorlin Syndrome After Positive Phase 2a Results
DermBiont, a clinical-stage biotech company specializing in innovative topical treatments for rare oncology and dermatology conditions, has reported promising initial results from its open-label, multi-center Phase 2a trial for basal…
IMFINZI® Granted Priority Review and Breakthrough Therapy Status for Limited-Stage SCLC in the US
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted by the FDA for Priority Review. This application, based on the positive ADRIATIC Phase III trial results in…
Commonwealth Care Alliance and Beth Israel Lahey Health Expand Provider Agreement
Commonwealth Care Alliance (CCA) has expanded its provider agreement with Beth Israel Lahey Health (BILH) to enhance care access for its Senior Care Options (SCO) and One Care members. This…
Trilliant Health Launches Free Provider Directory with Insights on 2.9M+ Providers
Trilliant Health, a top analytics firm in the healthcare sector, has introduced a free version of its Provider Directory application. This user-friendly tool offers a centralized source for precise and…
Alpenglow Biosciences and Partners Raise $24M for 3D Spatial Pathology Platform
Alpenglow Biosciences, a pioneer in 3D spatial biology, has recently received contracts from the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH). Additionally, the…
Success Beyond Game Day and XPE Integrate AI Mindset Training into SHREDmill Platform
Success Beyond Game Day and SHREDmill have partnered to integrate AI-driven mindset training into XPE’s SHREDmill platform and online community. This collaboration seeks to elevate the overall development of athletes…
Universal DX Launches Clinical Trial for Signal-C® Colorectal Cancer Blood Test FDA Approval
Universal DX (UDX) has completed its Series B funding round, which will support the clinical trial for its colorectal cancer screening blood test, Signal-C®. This trial is a key step…
Quince Therapeutics Announces ATTeST Trial Data Publication in The Lancet Neurology
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on utilizing patients’ own biology to treat rare diseases, has announced the online publication of data from its Phase 3 ATTeST…
Concentra Expands Telemedicine to Include Behavioral Health for Workers’ Comp
Concentra®, a leading provider of occupational medicine, has announced the introduction of its new behavioral health service on Concentra Telemed®, the company’s telemedicine platform for workers’ compensation. Concentra® has introduced…
Ontrak Health Achieves HITRUST CSF® Certification for 2024
Ontrak, Inc. (NASDAQ: OTRK), a top AI-driven and telehealth-enabled behavioral healthcare company, has earned HITRUST Risk-based, 2-year (r2) certification for the customer data exchange components of its Ontrak Advanced Engagement…
KalVista’s Sebetralstat Approved by EMA for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for…